Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021 : results from the European registry on H. pylori management (Hp-EuReg)
Olmedo, Llum (Althaia Xarxa Assistencial Universitària de Manresa)
Calvet, Xavier (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Gené Tous, Emilio (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Bordin, Dmitry S. (Tver State Medical University)
Voynovan, Irina (AS Loginov Moscow Clinical Scientific Center)
Castro-Fernandez, Manuel (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
Pabón-Carrasco, Manuel (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
Keco-Huerga, Alma (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
Perez-Aisa, Ángeles (Redes de Investigación Cooperativa Orientada a Resultados en Salud)
Lucendo, Alfredo J. (Instituto de Investigación Sanitaria de Castilla-La Mancha)
Rodrigo, Luís (Universidad de Oviedo)
Sarsenbaeva, Aiman S. (Chelyabinsk Regional Clinical Hospital)
Khlinov, Igor (Ural State Medical University)
Fadieienko, Galyna (Malaya Therapy National Institute of NAMS)
Zaytsev, Oleg (First Clinical Medical Centre)
Lanas, Angel (Instituto de Investigación Sanitaria de Aragón)
Martínez-Domínguez, Samuel J. (Instituto de Investigación Sanitaria de Aragón)
Alfaro, Enrique (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Jonaitis, Laimas (Lithuanian University of Health Sciences)
Núñez, Óscar (Universidad Francisco de Vitoria)
Pellicano, Rinaldo (Molinette-SGAS Hospital (Turin, Itàlia))
Hernández Villalba, Luis (Hospital Santos Reyes (Aranda de Duero, Castella i Lleó))
Gridnyev, Oleksiy (Malaya Therapy National Institute of NAMS)
Kupcinskas, Juozas (Lithuanian University of Health Sciences)
Gasbarrini, Antonio (Fondazione Policlinico Universitario Agostino Gemelli IRCCS)
Boltin, Doron (Tel Aviv University)
Niv, Yaron (Ariel University (Israel))
Babayeva, Gülüstan (Azerbaijan State Advanced Training Institute)
Marcos-Pinto, Ricardo (Center for Research in Health Technologies and Information Systems)
Tepes, Bojan (DC Rogaska (Eslovènia))
Venerito, Marino (University Hospital of Magdeburg (Alemanya))
Papp, Veronika (Semmelweis University (Hungria))
Lerang, Frode (Østfold Hospital Trust (Noruega))
Leja, Marcis (University of Latvia)
Phull, Perminder S. (Aberdeen Royal Infirmary (Aberdeen, Escòcia))
Marlicz, Wojciech (Centre for Digestive Diseases)
Doulberis, Michael (Kantonsspital Aarau (Suïssa))
Smith, Sinead M. (Trinity College Dublin)
Milivojevic, Vladimir (Belgrade University)
Kunovsky, Lumir (Masaryk Memorial Cancer Institute (Txèquia))
Mestrovic, Antonio (University Hospital of Split (Croàcia))
Matysiak-Budnik, Tamara (CHU de Nantes)
Simsek, Halis (Hacettepe University (Ankara, Turquia))
Cano-Català, Anna (Althaia Xarxa Assistencial Universitària de Manresa)
Puig, Ignasi (Universitat de Vic, Universitat Central de Catalunya (UVic-UCC))
Moreira, Leticia (Universitat de Barcelona)
Parra, Pablo (Instituto de Salud Carlos III)
Nyssen, Olga P. (Instituto de Salud Carlos III)
Megraud, Francis (Université de Bordeaux)
O'Morain, Colm (Trinity College Dublin)
P. Gisbert, Javier (Instituto de Salud Carlos III)
Universitat Autònoma de Barcelona

Data:	2024
Resum:	BACKGROUND: Bismuth quadruple therapies (BQTs) including bismuth, a proton pump inhibitor (PPI) and two antibiotics have been shown to be highly effective for treating Helicobacter pylori infection even in areas of high bacterial antibiotic resistance. OBJECTIVE: To describe the time trends of use, effectiveness and safety of BQT in Europe using the European Registry on Helicobacter pylori Management (Hp-EuReg). DESIGN: Patients registered in the Hp-EuReg from 2013 to 2021 who had received BQT were included. The regimens prescribed, the number of eradication attempts, effectiveness, adherence and safety were analysed. The effectiveness was assessed by modified intention to treat (mITT). Time-trend and multivariate analyses were performed to determine variables that predicted treatment success. RESULTS: Of the 49 690 patients included in the Hp-EuReg, 15 582 (31%) had received BQT. BQT use increased from 8. 6% of all treatments in 2013 to 39% in 2021. Single-capsule BQT-containing bismuth, metronidazole and tetracycline-plus a PPI (single-capsule BQT, ScBQT) was the most frequent treatment mode (43%). Schemes that obtained an effectiveness above 90% were the 10-day ScBQT and 14-day BQT using tetracycline plus metronidazole, or amoxicillin plus either clarithromycin or metronidazole. Only ScBQT achieved above 90% cure rates in all the geographical areas studied. Using the ScBQT scheme, adherence, the use of standard or high-dose PPIs, 14-day prescriptions and the use of BQT as first-line treatment were significantly associated with higher mITT effectiveness. CONCLUSION: The use of BQT increased notably in Europe over the study period. A 10-day ScBQT was the scheme that most consistently achieved optimal effectiveness. TRIAL REGISTRATION NUMBER: NCT02328131.
Ajuts:	European Commission 101095359
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Antibiotic Therapy ; Helicobacter Pylori ; Helicobacter Therapy
Publicat a:	Gut, Vol. 74 Núm. 1 (october 2024) , p. 15-25, ISSN 1468-3288

DOI: 10.1136/gutjnl-2024-332804
PMID: 39461739

11 p, 1.6 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d’Investigació i Innovació Parc Taulí (I3PT)
Articles > Articles de recerca
Articles > Articles publicats